Biomedical subjects
Publications and source records attributed to K E Thames.
A number of chemical modifications were made to purified human IgG1. The effects of these modifications on the complement activity of the immunoglobulin were studied using aggregation on latex and measuring the consumption of the complement by CH50-quantitation. Tryptophan and tyrosine are implicated in the complement fixing site of this human immunoglobulin, and an arginine moiety probably provides a binding site for the complement.
Explore the source record for details and available documents.
Indirect evidence for the complement-fixing site of human IgG1 has been found by using chemical modification of the immunoglobulin. These results implicate the amino acid residues, tryptophan, tyrosine, and arginine. Furthermore, by the use of synthetic peptides it has been shown that the area surrounding the tryptophan and tyrosine at positions 277 and 278 probably constitutes the locus of the complement-fixing site of human IgG1. By analogy, the tryptophan at position 488 of human IgM is implicated in the complement-fixing site of this immunoglobulin. Evidence for this is presented by a peptide which mimics the sequence 487-491 of human IgM and possesses the ability to consume complement. The relative complement-fixing ability of this peptide is 200 times less effective than human IgG1.
Explore the source record for details and available documents.